Breaks Categories: News

TuesdayMay 04, 2021 4:22 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Proven Pharmaceutical Exec as Chief Commercial Officer

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Ann Cunningham as its chief commercial officer. Cunningham, who has been and will continue serving on VTGN’s board of directors, has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing and global life cycle product management expertise in roles across several health care markets, including neuropsychiatry and other CNS markets that VistaGen is pursuing. “Since joining our board, Ann’s…

Continue Reading

TuesdayMay 04, 2021 12:19 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). An open-label, multicenter Phase 1/2 clinical trial, Acclaim-2 combines Genprex’s lead drug candidate, REQORSA(TM) immunogene therapy, with Merck & Co Inc.’s Keytruda in patients with late-stage NSCLC who are low expressors (1% to 49%) of the protein programmed death-ligand 1 ("PD-L1"). “Our clinical team remains focused on engaging with leading clinical investigators and esteemed research institutions in…

Continue Reading

MondayMay 03, 2021 10:07 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and training for the psychotherapeutic component of Tryp's clinical trial activities and will strengthen Tryp's capability to plan and implement clinical trials. The agreement will also enhance the company’s ability to make the most of the information gathered. Fluence has specific expertise in psychedelic clinical trials…

Continue Reading

ThursdayApr 29, 2021 1:45 pm

BioMedNewsBreaks – RYAH Group Inc. Featured in Bell2Bell Podcast

RYAH Group, engaged in the development and commercialization of various innovative technology solutions for the plant-based medical industry, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. RYAH’s CEO Gregory Wagner joined the latest episode to discuss the company’s 2021 goals and milestones, as well as provide an overview of RYAH’s business model and product offerings. “I came to the company two years ago, and the reason why I came here from a different career was because I was completely floored by the amount of data this…

Continue Reading

WednesdayApr 28, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Pursues Market Access in Israel for ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has delivered 2,000 of its rapid 25-minute PCR tests ("Covid-ID Lab") to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution. According to the update, the Israeli distributor markets and distributes a range of medical products and diagnostics in Israel and surrounding Middle Eastern countries. Its customers include government and private institutions such as hospitals, pharmacies and a broad range of health care providers. "We are excited by the opportunity to expand potential distribution…

Continue Reading

TuesdayApr 27, 2021 1:58 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Board Appointment of Dr. Joanne Curley

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Joanne Curley, Ph.D. to its board of directors. VistaGen’s board will be comprised of seven directors following Dr. Curley’s appointment. “Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas,” said Shawn Singh, chief executive officer of VistaGen. “Her track record of propelling seven products from early development through regulatory approval is impressive and reflects her extensive…

Continue Reading

MondayApr 26, 2021 2:24 pm

BioMedNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Announces LOI to Launch a Subscription-Based App

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer hearing device and hearing health technology space, has signed a letter of intent (“LOI”) with Audio Cardio Inc., dba AudioCardio(TM). The agreement provides InnerScope with a worldwide license, except for Japan, Korea and China, for full commercial rights to develop, market and sell an InnerScope-branded, subscription-based mobile app utilizing AudioCardio proprietary software. The software includes the  clinically proven Threshold Sound Conditioning technology. The proposed transaction outlined in the agreement provides for both InnerScope and AudioCardio to achieve greater market penetration by focusing on enhancing the visibility and awareness…

Continue Reading

WednesdayApr 21, 2021 3:33 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Achieves Critical Step Toward Commercial Sales of ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its entry into an agreement with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto's diagnostic products in Germany. According to the update, the agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab"). "With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of Covid-ID Lab," said Hugh Rogers, CEO and director of XPhyto. "The company's commercialization strategy…

Continue Reading

WednesdayApr 21, 2021 10:07 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer and diabetes; in addition, Varner will answer questions following each week’s presentation. The webinar series is slated to run from April 22 through June 10, 2021, and will begin at 11 a.m. EDT; each presentation is scheduled to last 30 minutes. The company also noted that a recorded version of each webinar would be available on the company website as…

Continue Reading

WednesdayApr 21, 2021 9:30 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Partnership to Offer Virtual Care for Patients with Diabetes

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is partnering with MediOrbis, a telehealth provider specializing in chronic conditions, to provide remote patient monitoring services to Medicare patients with diabetes. The new virtual care initiative means that Medicare patients who have diabetes and who are eligible can receive convenient virtual care that is covered under their existing Medicare benefits. The telehealth services are delivered by MediOrbis with remote patient monitoring through DarioHealth's AI-powered digital chronic care platform. The announcement noted that the new virtual care program will be available to Dario's approximately 75,000 members with diabetes. Because…

Continue Reading